MGC
Pharmaceuticals Ltd
Update
- Application for Admission to
Trading
19
February 2024
ASX, LSE:
MXC
MGC
Pharmaceuticals Ltd ("MGC
Pharma" or
the "Company") refers to its
announcement entitled "Application for Admission to Trading" which was released on 13
February 2024. The Company wishes to advise that the application to
admit 283,150 fully paid ordinary shares ("Admission Shares") to the Financial
Conduct Authority's Official List and to trading on the Main Market
of London Stock Exchange plc ("Admission") has been delayed. The
Admission Shares, having already been admitted to trading on the
Australian Stock Exchange ("ASX"), will not be affected by the
delay and will continue to be tradable on the ASX. The total number
of shares in issue and voting rights, being 43,851,631, remain
unchanged. The Company will provide a further update on the
Admission in due course.
-Ends-
Authorised for release by the Managing Director, for further
information please contact:
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC,
ASX: MXC) is a prominent European pharmaceutical company with a
strong commitment to creating accessible and ethically produced
cutting-edge medicines. Our approach combines in-house research
with innovative technologies, all aimed at discovering and
producing treatments for currently unmet medical
conditions.
The company's founders and executives
are distinguished figures in the global pharmaceutical industry.
Our central business strategy revolves around the development and
supply of innovative medicines, responding to the increasing demand
in the medical markets of Europe, North America, and
Australasia.
MGC Pharma maintains a robust
development pipeline that addresses two prevalent medical
conditions, with additional products currently in the developmental
stages. We've established strategic partnerships with renowned
institutions and academia, fostering the optimization of our
medicines' development. These medicines are produced in our EU-GMP
Certified manufacturing facilities, ensuring the highest quality
standards.
With a growing patient base in key
regions like the USA, UK, Australia, and Ireland, MGC Pharma has
also built a global distribution network through a wide-reaching
group of commercial partners. This extensive network places us in a
prime position to supply the global market effectively.
Follow us through our social media
channels:
LinkedIn: MGC Pharmaceuticals
Ltd.
Twitter: @MGC_Pharma
Facebook:
@mgcpharmaceuticals
Instagram: @mgc_pharma